The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

CORRECT: UK BROKER RATINGS SUMMARY: Shore Keeps Asos At Sell

Mon, 14th Oct 2019 11:06

(Correcting that Shore kept Asos at Sell, having cut from Hold back in July.)

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

----------

FTSE 100

----------

CREDIT SUISSE CUTS SSE TO 'NEUTRAL' ('OUTPERFORM') - TARGET 1250 PENCE

----------

SOCGEN RAISES SSE PRICE TARGET TO 1400 (1300) PENCE - 'BUY'

----------

INVESTEC CUTS MEGGITT TO 'HOLD' ('BUY') - TARGET 640 (610) PENCE

----------

GOLDMAN RAISES WPP PRICE TARGET TO 1200 (1150) PENCE - 'BUY'

----------

GOLDMAN RAISES CRH PRICE TARGET TO 34 (33) EUR - 'NEUTRAL'

----------

CFRA CUTS MONDI PRICE TARGET TO 1800 (1850) PENCE - 'BUY'

----------

JPMORGAN CUTS OCADO TO 'UNDERWEIGHT' ('NEUTRAL') - TARGET 1050 (1073) PENCE

----------

RBC CUTS FRESNILLO PRICE TARGET TO 660 (770) PENCE - 'SECTOR PERFORM'

----------

JEFFERIES CUTS NMC HEALTH PRICE TARGET TO 1925 (1986) PENCE - 'UNDERPERFORM'

----------

CANTOR FITZGERALD RAISES GLAXOSMITHKLINE TO 'BUY' (HOLD) - TARGET 2000 (1450) PENCE

----------

REDBURN CUTS RECKITT BENCKISER TO 'SELL' (NEUTRAL)

----------

FTSE 250

----------

INVESTEC RAISES QINETIQ TO 'BUY' ('HOLD') - TARGET 350 (310) PENCE

----------

UBS CUTS MEDICLINIC INTERNATIONAL PRICE TARGET TO 385 (395) PENCE - 'BUY'

----------

BARCLAYS CUTS MAN GROUP PRICE TARGET TO 180 (195) PENCE - 'OVERWEIGHT'

----------

BARCLAYS CUTS JUPITER FUND PRICE TARGET TO 310 (350) PENCE - 'UNDERWEIGHT'

----------

MACQUARIE RAISES DRAX TO 'OUTPERFORM' ('NEUTRAL') - TARGET 350 (280) PENCE

----------

BERENBERG RAISES HOCHSCHILD MINING TO 'HOLD' ('SELL') - TARGET 180 (190) PENCE

----------

PEEL HUNT RAISES SENIOR TO 'BUY' ('HOLD')

----------

CREDIT SUISSE RAISES PENNON GROUP PRICE TARGET TO 700 (650) PENCE - 'UNDERPERFORM'

----------

OTHER MAIN MARKET AND AIM

----------

SHORE CAPITAL KEEPS ASOS AT 'SELL' (CUT FROM 'HOLD' ON JULY 18)

----------

PANMURE RAISES PETRA DIAMONDS TO 'BUY' ('HOLD') - TARGET 1380 (2300) PENCE

----------

INVESTEC RAISES DE LA RUE TO 'BUY' ('HOLD') - TARGET 310 PENCE

----------

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.